IDEXX Laboratories Cash Flow Statement
NASDAQ: IDXXHealthcareDiagnostics & ResearchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories free cash flow
In fiscal 2025, IDEXX Laboratories generated $1.18 billion of operating cash flow and spent $124.7 million on capital expenditures. That left free cash flow of $1.06 billion, a free-cash-flow margin of 24.6% of revenue. Free cash flow was up 30.8% from the prior year's $808.1 million.
IDEXX Laboratories returned $1.22 billion to shareholders through share repurchases, equal to 115% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.06B | 887.87M | 845.04M | 679.09M | 744.84M | 582.13M | 427.79M | 377.05M | 263.27M | 222.05M |
| Net Income growth (YoY) | +19.33% | +5.07% | +24.44% | -8.83% | +27.95% | +36.08% | +13.46% | +43.22% | +18.56% | +15.57% |
| Depreciation & Amortization | 145.18M | 129.94M | 114.91M | 111.90M | 104.60M | 96.00M | 88.01M | 83.18M | 83.14M | 78.22M |
| Stock-Based Compensation | 60.01M | 60.30M | 59.74M | 49.77M | 37.76M | 30.95M | 39.28M | 25.16M | 23.52M | 19.89M |
| Change in Working Capital | -71.16M | -52.57M | -86.11M | -170.68M | -82.38M | -92.00M | -70.18M | -91.64M | -39.04M | -5.12M |
| Operating Cash Flow | 1.18B | 929.00M | 906.51M | 542.98M | 755.55M | 648.06M | 459.16M | 400.08M | 373.28M | 338.94M |
| Capital Expenditures | -124.68M | -120.92M | -133.63M | -148.84M | -119.55M | -106.96M | -154.97M | -115.75M | -74.38M | -64.79M |
| Investing Cash Flow | -136.24M | -207.06M | -125.25M | -195.35M | -292.97M | -109.38M | -205.53M | 138.60M | -138.69M | -90.79M |
| Share Repurchases | -1.22B | -837.03M | -71.92M | -819.71M | -746.78M | -182.81M | -301.66M | -369.32M | -282.56M | -304.09M |
| Debt Issued | — | — | — | 0 | 0 | 200.00M | 100.00M | 0 | 0 | — |
| Debt Repaid | -178.38M | -75.00M | -75.00M | -75.00M | -50.00M | 0 | 0 | — | — | — |
| Financing Cash Flow | -1.16B | -878.07M | -442.00M | -370.94M | -697.41M | -248.42M | -286.41M | -597.80M | -208.02M | -222.20M |
| Net Change in Cash | -108.20M | -165.67M | 341.39M | -31.91M | -239.47M | 293.60M | -33.47M | -63.88M | 32.77M | 25.91M |
| Free Cash Flow | 1.06B | 808.08M | 772.88M | 394.15M | 636.00M | 541.11M | 304.19M | 284.33M | 298.89M | 274.16M |
This table shows 10 annual periods of IDEXX Laboratories's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IDXX's reporting calendar. What is a cash flow statement?